Lithium is the new oil AND, Smackover is America's new wellhead!

 

⚡ Investment Report: Smackover Lithium Project

Joint Venture between Standard Lithium Ltd. (NYSE: SLI / TSX-V: SLI) and Equinor ASA (NYSE: EQNR)

---

🧭 Executive Summary

As America and China continue to lock horns over critical minerals and strategic materials, smaller North American players — Standard Lithium (SLI), Critical Metals Corp (CRML), Ucore Rare Metals (UCU), MP Materials (MP), and Avalon Advanced Materials (AVL) — are poised to thrive. These companies control valuable deposits of lithium, rare earths, and other critical minerals that underpin the global energy transition.

Among them, the Smackover Lithium Project stands out as one of the most strategically positioned and technically advanced lithium ventures in North America. With Standard Lithium as operator and Equinor ASA as a 45% partner, this project is well‑funded, technologically mature, and fully aligned with U.S. energy independence and clean‑tech industrial policy goals.

---

🌍 Geological & Strategic Context

🔹 The Smackover Formation

• A geological giant stretching across the Gulf Coast Basin, running through southern Arkansas and eastern Texas.

• Formed by porous carbonate rock layers that host brine rich in lithium and other dissolved minerals.

• Already home to a mature industrial brine extraction ecosystem, historically focused on bromine production — creating ideal infrastructure for lithium development.

🔹 Project Zones

• Southwest Arkansas (SWA) Project: Core area of lithium concentration with average 437 mg/L lithium; planned capacity of 30,000 tonnes/year battery‑grade LiOH.

• East Texas Project: Expanding zone where brine samples have shown up to 806 mg/L lithium concentrations.

• Both project areas are contiguous within the subsurface Smackover geological system, forming a unified development corridor.

---

⚙️ Technology & Operations

Direct Lithium Extraction (DLE)

• Proprietary process developed by Standard Lithium; continuously operated pilot plant in El Dorado, AR since 2020.

• >99% lithium recovery demonstrated, with minimal land and water use compared to evaporation ponds.

• Produces high‑purity lithium hydroxide suitable for EV batteries.

• Significantly shorter production cycles and lower carbon footprint.

---

🤝 Joint Venture Structure — "Smackover Lithium"

Partner	Role	Ownership
Standard Lithium (SLI)	Project operator, technology owner	55%
Equinor ASA (EQNR)	Strategic investor, subsurface & capital partner	45%

• Equinor committed:

  • $30M upfront payment

  • $60M development work program

  • Up to $70M in milestone-based performance payments

• DOE Grant: $225M awarded (January 2025) for Phase 1 SWA construction.

• Operating JV name: Smackover Lithium — a separate entity governed jointly, designed to scale projects across the Smackover Basin.

---

💰 Financial and Partner Strength

Standard Lithium Ltd. (SLI)

• Cash reserves: $31.2M (Dec 2024)

• Debt: None

• 100% operator of Smackover Lithium JV assets

• Positioned as one of the few pure‑play U.S. lithium developers

Equinor ASA (EQNR)

• Market Cap: ~$90B

• P/E: 7.8×

• P/S (TTM): 0.6

• P/CF (TTM): 3.6×

• Operating Margin: 28.4%

• Dividend Yield: 8.4%

• Strategic energy supermajor from Norway with deep pockets and global project execution capacity.

• Expanding beyond hydrocarbons into low‑carbon, critical‑minerals, and hydrogen sectors.

“Energy – Europe – America – Equinor ASA. P/E 7.8x, Dividend 8.4% — Nuff Said.”

---

🧱 Development Roadmap

Milestone	Timeline	Status
JV Formation with Equinor	Q1 2025	✅ Completed
DOE $225M Grant Secured	Q1 2025	✅ Completed
FEED & Engineering Studies	Q2–Q3 2025	🔄 In Progress
Construction Start (SWA Phase 1)	Late 2025 – Early 2026	🔜 Planned
East Texas Resource Expansion	2025–2026	🔄 Active
Commercial Production Launch	2027 (est.)	🕒 Target

---

📈 Investment Thesis

1. Strategic Resource Control: SLI and Equinor control one of North America’s richest lithium brine systems.

2. Government Support: DOE grant validates technical and geopolitical importance.

3. Technology Edge: Proven DLE technology de‑risks extraction and accelerates scalability.

4. Institutional Partner: Equinor’s financial strength ensures long‑term project execution.

5. Critical Mineral Supercycle: Geopolitical friction between the U.S. and China will continue to amplify the value of domestic lithium production.

We are long both SLI and EQNR. The combination of technology, capital, and national priority creates a unique, asymmetric upside in the North American lithium sector.

---

⚠️ Risks & Mitigations

Risk	Impact	Mitigation
DLE Scale-Up Risk	Technical challenge in commercial scaling	Multi‑year pilot proven, DOE oversight ensures compliance
Permitting/Regulatory	Potential local or state delays	Favorable Arkansas regulatory climate; existing brine infrastructure
Lithium Price Volatility	Market-driven revenue swings	U.S. IRA incentives, potential offtake contracts, DOE-supported floor pricing
CapEx Inflation	Rising material costs	Equinor funding cushions; DOE grant offsets 20–30% of initial capex

---

🌎 Macro Context: The Critical Mineral Rivalry

The U.S.–China rivalry over energy transition materials has escalated into a strategic resource race. Lithium, nickel, and rare earths have emerged as the new oil — essential to EVs, grid storage, and defense applications.

Small-cap developers like SLI, CRML, UCU, MP, and AVL occupy a unique sweet spot:

• They own the feedstock of the next industrial era.

• They are becoming acquisition targets for major energy and materials firms (e.g., Equinor, ExxonMobil, Rio Tinto).

• They provide investors with exposure to critical mineral leverage without megacap dilution.

---

🧩 Conclusion

The Smackover Lithium Project is more than a single asset — it is a strategic partnership between innovation (SLI) and institutional power (Equinor), underpinned by U.S. government backing.

With world-class geology, proven technology, strong partners, and policy tailwinds, Smackover Lithium is positioned to become a cornerstone of America’s clean energy supply chain.

→ In short:

Lithium is the new oil. Smackover is America’s wellhead.

---

Intel this year looks to me like the Blackberry Stock of 20 years ago!

 

I believe that, my analogy (to BlackBerry) is useful: 

Something that was once dominant, lost its footing, and then struggled to adapt

For Intel there are real warning signs.

1. Lost leadership in foundry / logic
   Intel has ceded manufacturing leadership to TSMC and Samsung in advanced nodes. Its delays, yield problems, and missteps eroded competitive advantage.

2. Execution risk is high
   Reviving a foundry business with new process nodes, scaling fab expansion, controlling costs, and securing customers is extremely difficult — many have tried and failed.

3. Financial pressure
   The company has had losses, heavy capital expenditure burdens, and the need to service debt and fund new fabs puts margin stress.

4. Dependence on government / subsidies
   A large part of the current “tailwinds” is from government support (CHIPS Act, grants, equity infusion). That introduces political risk, uncertainty, and potential distortions. The $8.9B U.S. government investment for a ~9.9% stake is a key signal. Newsroom+1

5. Unclear path to dominance
   Even with new fabs and subsidies, there’s no guarantee that Intel can win back major customers (like Apple, AMD, NVIDIA, etc.) or regain logic/advanced node prestige.

6. Market expectations may already be rich / too optimistic
   The recent jump in stock price might already embed bullish expectations of successful turnaround, leaving little margin for error.

---

Why I don't own, and would not short Intel at this time!

What works against a pure “short / dead cat bounce” thesis

There are also significant counterarguments and asymmetric upside risks that caution against overly pessimistic positioning.

1. Strong government backing
   The U.S. government is actively supporting Intel both via grants and equity. That tends to reduce downside—governments tend to avoid letting big “strategic” players fail outright. The government ownership is passive (no board seats) per announcements. GovCon Wire+1

2. Strategic importance & political protection
   Semiconductor sovereignty is a national-security issue. Intel as one of the last large U.S.-based advanced logic players has a “too big to fail / too strategically important to let collapse” angle. That could lead to further policy support, protection, or bailouts if things go badly.

3. Recent partnerships and capital infusions
   For example, NVIDIA invested ~$5B in Intel in 2025, which is a vote of confidence (or at least strategic alignment) in Intel’s roadmap. WIRED+2Barron's+2

4. Turnaround upside if execution works
   If Intel can deliver new process nodes, yields, win foundry customers, and scale better, the upside is large — the stock could re-rate. The current valuation likely discounts that, meaning a good outcome could yield significant gains.

5. Volatility / mispricing opportunities
   In a turnaround/restructuring scenario, the stock may swing wildly, making timing critical (shorts can be punished in big rebounds).

---

Recent stock dynamics & valuation

Intel Corp. (INTC)

$36.37

+$19.02(+109.63%)Max

$35.65-$0.72(-1.98%)Open38.50

Volume183.1M

Day Low33.96

Day High39.63

Year Low17.67

Year High39.65

• The current share price is showing volatility, which is typical in “recovery / turnaround” stories.

• Analysts recently downgraded the stock, warning that recent rallies may be overdone. Barron's

• The recent run-up has been partly driven by announcements of government and strategic investments, which may reflect sentiment more than fundamentals. (A 4th "Dead Cat" bounce)

---

My view: cautious, but not a full “short first” conviction

Healthy skepticism is in order here. Intel is not yet out of the woods, and structural risks are real. But I’m more nuanced in my assessment:

• I wouldn’t place a large, unhedged short as a default — the potential for a positive surprise (or political/strategic lifeline) is real. (Or another "dead cat" bounce)

• If I were to take a short position, I’d structure it with tight risk controls (stop losses, hedges) and treat it as a tactical play rather than a belief that Intel is irrecoverable.

• I’m more comfortable holding a bearish option strategy (e.g. long put or put spread) to limit downside and preserve upside optionality, rather than a naked short.

Intel's "Tell"!
To me, Intel looks a lot like Blackberry Stock of 20 years ago.
Deadcat bounce after deadcat bounce until 90% disappeared!

I believe my analogy (to BlackBerry) is useful:  

I wouldn't touch this stock with your 10 ft pole!!!

Silver/Gold trade: With precious metals popping to ATH's, we bought shares of Coeur Mining Inc NYSE:CDE - Here's why!

 

Coeur Mining Corp

Revised Scenario (2025–2027, with $4,000 gold / $50 silver)

Case	Assumptions	Revenue (est.)	FCF (est.)	Stock Potential
Bull (now baseline)	Gold $4,000+, Silver $50, steady ops, costs flat	$2.5–2.8B	$1.0–1.2B+	Stock could 2–3× from here (i.e., $40–$60/share)
Base (pullback)	Gold $3,000–3,500, Silver $35–40	$1.8–2.2B	$600–800M	Stock could +50–100%
Bear (deep correction)	Gold <$2,500, Silver <$25	$1.0–1.4B	Break-even to $200M	Stock could retrace to –40–60% from current

---

⚖️ Here’s a simplified list of the main institutional investors in Coeur Mining (CDE):

---

🏦 Biggest Holders

• Vanguard Group – about 10%

• BlackRock – about 9%

• Van Eck (GDXJ / gold miner funds) – about 6–7%

• State Street (SSGA) – about 3–4%

• Mirae Asset Global Investments – about 2–3%

• Dimensional Fund Advisors – about 2–3%

• Geode Capital (index manager for Fidelity funds) – about 2–3%

• Arrowstreet Capital – about 1–2%

• Sprott Inc. – about 1–2% (specialist in gold/silver)

---

✅ Key point: Roughly 70–75% of CDE is owned by institutions, with the big ETF managers (Vanguard, BlackRock, Van Eck) holding the largest stakes.

Investment Takeaway Under Current Prices

• CDE transforms from a mid-tier producer into a “cash-machine” with strong leverage to silver.

• The SilverCrest acquisition (Las Chispas) now looks prescient — it greatly increased CDE’s silver exposure right before an all-time-high rally.

• Compared to majors (Newmont, Agnico), CDE’s torque to silver is higher, so its upside is greater.

• Risk remains (prices could correct, mining hiccups, integration risk), but in a $4,000 gold / $50 silver environment, CDE should massively outperform.

As the U.S. Government invests more and more in precious metals and Lithium, I think it's possible that, Standard Lithium, $SLI could be next!

 

Equinor is their backer with a big share of the "Smackover" project,
Which is situated in both Texas and Arkansas.
We are long SLI and also long EQNR and here's why...

Energy - Europe - America - Equinor ASA NYSE: $EQNR
P/E Ratio 7.8x - Price/Sales (TTM) 0.6 - Price/Cash Flow (TTM) 3.6x
Operating Margin 28.4% - Dividend 8.4% - Nuff Said!!!
https://lnkd.in/gn52ddc9

Related Articles:

SLI's Smackover could be one of the richest Lithium Brine projects in the world, and it's located in Texas and Arkansas

retirefunds.blogspot.com

CABA - Why we like this microcap Bio Tech Stock!

 Cabaletta Bio (CABA) as of October 3, 2025 — Added to position!

(Ed Note: As I've said before, some penny stocks should not be overlooked - CABA is one of those)

Using the latest financials, ownership, analyst targets, and pipeline status here's the review.

---

✅ Reasons to Keep Adding

1. Institutional support is strong

• Bain, Adage, Alyeska, Jennison, Cormorant and others each hold 5–10% stakes. These aren’t casual positions; they’re sophisticated biotech funds that are often early to clinical-stage winners.

• Heavy crossover investor involvement means better access to capital markets when CABA next raises funds.

2. Solid financial runway (for now)

• ~$195M cash (as of June 30, 2025), runway into 2H 2026. That buys them time to generate pivotal registrational data before another raise.

3. Clinical progress is de-risking

• At EULAR 2025, 7/8 myositis patients showed strong improvements (TIS responses, off immunomodulators).

• FDA alignment for a 2027 BLA in myositis gives a visible regulatory path.

4. Analyst upside remains significant

• Consensus price targets: $11–$15 (some as high as $22–25), versus current ~$2.

• Analysts are modeling hundreds of percent upside if trials continue to track positively.

5. Takeover potential

• If registrational cohorts replicate early efficacy, CABA is a prime target for AbbVie, J&J, Novartis, Gilead, or Roche — all looking at autoimmune CAR-T.

• A buyout before or after pivotal data isn’t far-fetched.

---

⚠️ Reasons to Be Cautious

1. Cash burn is steep

• Q2’25 R&D was ~$37.6M; expenses are climbing as registrational trials expand. They will likely raise again before approval, leading to dilution.

2. Execution risk

• Autologous CAR-T is complex. Manufacturing at scale (via Lonza & Oxford Biomedica) is unproven in autoimmune vs oncology. Delays or CMC issues could derail timelines.

3. Safety watch

• One lupus nephritis patient had a Grade 4 ICANS event previously (resolved, but a reminder). Larger N could surface new safety issues.

4. Option repricing optics

• Management repriced insider options down to $1.92 in May 2025. This aligns incentives but some investors view it as “shareholder unfriendly.”

5. Long road to revenue

• No approved products. Even in the bull case, first revenues come post-2027. Near-term, this is a binary pipeline play.

---

🎯 Balanced Take

• If you're risk-tolerant and comfortable with clinical-stage biotech volatility, adding here is a speculative bet with very high upside. 

• The current price (~$2) is well below analyst consensus ($11–15), and institutional buying in August suggests smart money is still leaning bullish.

• If you want stability, remember this is still all-or-nothing science. One bad dataset could crater the stock. You may want to size your position carefully, treat it as a satellite/speculative play, as we have and be ready for dilution.        Here are previous articles on CABA!

  Been adding to CABA Bio stock this month. Here's why!

  
  
  Cures for antoimmune diseases such as MD, Lupus, Mytosis MS and others are targets for this cutting edge, Bio Tech microcap!

• Will the New developments from Cabaletto Bio (CABA) make it a takeover target? Stay tuned!

A U.S. Government Shutdown will affect these companies much more than others!

 

A data-backed, “most exposed” list focused on companies where U.S. federal work is a big slice of revenue (or the core business) 

Grouped by exposure bands and citing recent filings/rankings.

Ultra-high exposure (≈80–100%+ tied to U.S. federal work)

1. SAIC (SAIC) — ~98% of revenue from U.S. Gov’t (prime or sub). SEC

2. Booz Allen Hamilton (BAH) — reporting pegs U.S. Gov’t at ~98% of revenue. The Wall Street Journal+1

3. Leidos (LDOS) — ~87% from U.S. Gov’t. SEC+1

4. Northrop Grumman (NOC) — 87% to U.S. Gov’t (2024). SEC

5. HII (HII) — military shipbuilding; U.S. Gov’t orders comprise “substantially all” backlog. SEC

6. CACI (CACI) — business overwhelmingly U.S. Gov’t; disclosures show ~97% domestic (U.S. agency-focused). TradingView+1

7. V2X (VVX) — “substantial majority” of revenue from U.S. Gov’t; DoD-centric services. Q4 Capital

Very high exposure (≈60–80%)

8. BWX Technologies (BWXT) — ~76% from U.S. Gov’t (Navy reactors, DOE/NNSA). BWX Technologies Investors

9. Lockheed Martin (LMT) — 73% from U.S. Gov’t (65% DoD). SEC

10. General Dynamics (GD) — 69% from U.S. Gov’t. SEC

11. L3Harris (LHX) — ~74% in Q1’25 from U.S. Gov’t (incl. FMS). Fintel

12. KBR (KBR) — 57% from U.S. Gov’t (FY2024). Q4cdn

High exposure (≈40–60%)

13. RTX (RTX) — U.S. Gov’t ~45% of net sales (ex-FMS). RTX Investors

14. Parsons (PSN) — Federal is a core segment; multiple U.S. federal customer sets each >20% of revenue (heavy federal mix). SEC

15. Maximus (MMS) — Gov’t outsourcing specialist (federal + state); filings show predominantly U.S. program revenue with growing federal exposure. Maximus, Inc.+1

Material exposure (program-critical, though more diversified)

16. Palantir (PLTR) — Gov’t still ~55% of FY2024 revenue; U.S. Gov’t growth +53% Y/Y in Q2’25. Visual Capitalist+1

17. Mercury Systems (MRCY) — Defense electronics pure-play; revenue is predominantly U.S. defense primes/programs. SEC

18. Kratos (KTOS) — Tactical drones/space & defense; revenue largely from U.S. DoD/IC programs. Kratos Defense+1

19. AeroVironment (AVAV) — DoD small UAS/missiles; mix varies with FMS/international but U.S. programs remain core drivers. Aviation Investor+1

20. Huntington Ingalls’ peers / Big 5 integrators (context) — The Top 100 Federal Contractors ranking (FY2024 awards) underscores Leidos, Booz Allen, Lockheed, GD, RTX, L3Harris, SAIC, NOC, CACI as the biggest prime recipients — i.e., most operationally exposed to any shutdown pauses in awards/funding flow. Washington Technology

---

Why these names are most at risk in a shutdown

• Revenue concentration: The first dozen derive a majority of sales from the federal wallet; a pause in new awards, mods, or payments hits quickly. (See %s above.)

• Procurement pipeline sensitivity: Top rankings in federal contract awards (Leidos, BAH, LMT, GD, RTX, LHX, SAIC, NOC, CACI) signal heavy reliance on award timing/obligation flow. Washington Technology

• Agency dependence: IT/consulting contractors (BAH, SAIC, LDOS, CACI, PSN, KBR, VVX, MMS) feel shutdowns faster than multi-year, already-appropriated hardware programs, though even primes see new starts and mods slow. (Industry advisories and coverage highlight this dynamic.) Bloomberg Law

Note: Rankings like Washington Technology Top 100 and BGOV200 show who’s biggest by federal obligations (a proxy for exposure), while 10-Ks give the percentage of total company revenue tied to the U.S. Government. For shutdown risk, both matter. Washington Technology+1